Real‑world treatment outcomes among patients with metastatic pancreatic cancer in Japan: The Tokushukai real‑world data project
R Shimoyama, Y Imamura, K Uryu… - Molecular and …, 2023 - spandidos-publications.com
The present study aimed to investigate temporal trends in treatment patterns and prognostic
factors for overall survival (OS) among patients with metastatic pancreatic cancer. From the …
factors for overall survival (OS) among patients with metastatic pancreatic cancer. From the …
[HTML][HTML] A prospective phase II study of biweekly S-1, leucovorin, and gemcitabine in elderly patients with locally advanced or metastatic pancreatic adenocarcinoma …
Background Elderly patients with advanced pancreatic adenocarcinoma (APC) are
conceived to be frailer and susceptible to treatment toxicity that has led to disparity in lower …
conceived to be frailer and susceptible to treatment toxicity that has led to disparity in lower …
Role of conversion surgery for unresectable pancreatic cancer after long-term chemotherapy
N Tsuchiya, R Matsuyama, T Murakami… - World Journal of …, 2020 - Springer
Background Unresectable pancreatic cancer (UR-PC) has a poor prognosis. Although
conversion surgery has been considered a promising strategy for improving prognosis in UR …
conversion surgery has been considered a promising strategy for improving prognosis in UR …
Single-center risk factor analysis for FOLFIRINOX associated febrile neutropenia in patients with pancreatic cancer
Purpose FOLFIRINOX is the standard therapy in patients with unresectable pancreatic
cancer (PC). However, FOLFIRINOX frequently induces febrile neutropenia (FN) and …
cancer (PC). However, FOLFIRINOX frequently induces febrile neutropenia (FN) and …
A phase I trial of oxaliplatin, irinotecan, and S-1 combination therapy (OX-IRIS) as chemotherapy for unresectable pancreatic cancer (HGCSG 1403)
Y Kawamoto, H Nakatsumi, K Harada… - The …, 2021 - academic.oup.com
Abstract Lessons Learned Because S-1 is orally administered, OX-IRIS does not necessitate
the continuous infusion of 5-FU and is more convenient. The recommended dose of OX-IRIS …
the continuous infusion of 5-FU and is more convenient. The recommended dose of OX-IRIS …
Phase II clinical trial of gemcitabine plus oxaliplatin in patients with metastatic pancreatic adenocarcinoma with a family history of pancreatic/breast/ovarian/prostate …
N Okano, C Morizane, S Nomura, H Takahashi… - International Journal of …, 2020 - Springer
Background A family/personal history of breast, ovarian, or pancreatic cancer is a useful
predictive marker for response to platinum-based chemotherapy in treating patients with …
predictive marker for response to platinum-based chemotherapy in treating patients with …
[HTML][HTML] Comparing the cost-effectiveness of FOLFIRINOX, nab-paclitaxel plus gemcitabine, gemcitabine and S-1 for the treatment of metastatic pancreatic cancer
M Kurimoto, M Kimura, E Usami… - Molecular and …, 2017 - spandidos-publications.com
The recommended chemotherapy regimens for pancreatic cancer include the combination
of 5-fluorouracil/leucovorin, oxaliplatin and irinotecan (FOLFIRINOX), nab‑paclitaxel (nab …
of 5-fluorouracil/leucovorin, oxaliplatin and irinotecan (FOLFIRINOX), nab‑paclitaxel (nab …
Phase I study assessing the feasibility of the triple combination chemotherapy of SOXIRI (S-1/oxaliplatin/irinotecan) in patients with unresectable pancreatic ductal …
H Yanagimoto, S Satoi, M Sho, T Akahori… - Cancer chemotherapy …, 2016 - Springer
Background The objective of this study was to determine the recommended dose (RD) of a
biweekly S-1, oxaliplatin, and irinotecan (SOXIRI) regimen in patients with unresectable …
biweekly S-1, oxaliplatin, and irinotecan (SOXIRI) regimen in patients with unresectable …
Prognostic factor in patient with recurrent pancreatic adenocarcinoma
T Sumiyoshi, K Uemura, R Shintakuya, K Okada… - … Archives of Surgery, 2023 - Springer
Purpose To elucidate prognostic factors for post-recurrence survival in patients with
pancreatic ductal adenocarcinoma (PDAC). Methods Patients who underwent curative-intent …
pancreatic ductal adenocarcinoma (PDAC). Methods Patients who underwent curative-intent …
Liver metastases from pancreatic ductal adenocarcinoma: is there a place for surgery in the modern era?
K Imai, GA Margonis, J Wang, CL Wolfgang… - Journal of …, 2020 - mednexus.org
Pancreatic ductal adenocarcinoma (PDAC) represents one of the most aggressive
malignancies, and the majority of patients with PDAC present with metastatic disease …
malignancies, and the majority of patients with PDAC present with metastatic disease …